at www.tipranks.com (Thu, 5-Nov 5:31 PM)
Insmed’s Sinus Study Reaches Completion: What INSM Investors Should Watch
at www.tipranks.com (Wed, 4-Nov 11:30 AM)
Insmed (INSM) Receives a Buy from Leerink Partners
at www.tipranks.com (Mon, 2-Nov 11:42 AM)
Insmed Advances New Lung Disease Study as TPIP Trial Continues
at www.tipranks.com (Mon, 2-Nov 11:31 AM)
Barclays Remains a Buy on Insmed (INSM)
at www.tipranks.com (Mon, 2-Nov 3:56 AM)
Insmed Earnings Call Highlights BRINSUPRI Growth and Pipeline
at www.tipranks.com (Sun, 1-Nov 7:20 PM)
Insmed soars as BRINSUPRI hits $400.10 million in Q3 revenue and 2026 guidance rises
Market Chameleon (Thu, 29-Oct 11:05 AM)
Insmed’s Q3 2026 revenue jump to $524.40 million was powered by BRINSUPRI’s $400.10 million quarter
Market Chameleon (Thu, 29-Oct 7:51 AM)
Market Chameleon (Mon, 19-Oct 9:12 AM)
Insmed Sets CFO Exit Date as It Reaffirms 2026 Revenue Guidance for BRINSUPRI and ARIKAYCE
Market Chameleon (Mon, 5-Oct 11:51 AM)
Insmed (INSM) CFO to Step Down After Nearly Seven Years as Company Reaffirms 2026 Revenue Guidance
Market Chameleon (Mon, 5-Oct 7:30 AM)
Insmed Wins FDA Priority Review for ARIKAYCE sNDA, Setting a January 28, 2027 PDUFA Date
Market Chameleon (Mon, 21-Sep 8:39 AM)
Insmed Lifts Revenue Targets, Reports Breakout Second Quarter on Brensocatib and Pipeline Progress
Market Chameleon (Thu, 6-Aug 11:14 AM)
Insmed Lifts Revenue Outlook as BRINSUPRI Surges 49% in Q2 and Pipeline Expands
Market Chameleon (Thu, 6-Aug 7:45 AM)
